Microbiology

PacBio Names Lara Toerien as Vice President and General Manager for the Americas

Retrieved on: 
Thursday, January 13, 2022
Molecule, Securities Exchange Act of 1934, Research, Technology, Abraxis BioScience, University of California, San Diego, Biology, General manager, Genomics, Growth, NASDAQ, Pacific Biosciences, GLOBE, Leadership, Microbiology, U.S. Securities and Exchange Commission, Attitude, Single-molecule real-time sequencing, Infection, Private Securities Litigation Reform Act, Company, Genetic variation, Invitrogen, Pennsylvania State University, Cancer, Biomedical Research, Cell biology, Security (finance), Thermo Fisher Scientific, University, Pharmaceutical industry, Antibiotics

MENLO PARK, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate, sequencing platforms, welcomes Lara Toerien, Ph.D., as Vice President and General Manager for the companys Americas region.

Key Points: 
  • MENLO PARK, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate, sequencing platforms, welcomes Lara Toerien, Ph.D., as Vice President and General Manager for the companys Americas region.
  • Lara is a genomics industry veteran with 25 years of experience in commercial roles of increasing responsibility.
  • I look forward to partnering with Peter Fromen and the PacBio team to expand the use of PacBios unique long read sequencing technology across the Americas, said Lara Toerien, Ph.D., Vice President and General Manager for Americas at PacBio.
  • Im excited to continue the expansion of the PacBio Americas team to serve this growing customer base.

Eagle Genomics and Quadram Institute's New Strategic Partnership to Accelerate Microbiome Analysis Through AI-Augmented Knowledge Discovery Platform

Retrieved on: 
Thursday, January 13, 2022
Knowledge, Population health, Business development, Biotechnology and Biological Sciences Research Council, Nature, Research, Plant, Human, East Anglia, List of genetics research organizations, Food chain, Norwich Research Park, Carbon, Data science, Biology, Earlham Institute, Genomics, BBSRC, Genome, Severe acute respiratory syndrome coronavirus 2, Population, Gene, Soil, Beauty, Deep tech, CEO, Biotechnology, Microbiology, Health, Bacteria, Tissue, Animal, Reading, Food, Environment, Agriculture, Norfolk and Norwich University Hospitals NHS Foundation Trust, Laboratory, Workflow, Organization, Partnership, University of East Anglia, Pharmaceutical industry, Antibiotics, Industrial design, Dietary supplement, Health care, NORWICH, Quadram Institute

"At Eagle Genomics,we firmly believe that the microbiome has a critical role to play across numerous industries, both now and inthe future.

Key Points: 
  • "At Eagle Genomics,we firmly believe that the microbiome has a critical role to play across numerous industries, both now and inthe future.
  • Dr. Roberto Zanchi, Head of Business Development, Quadram Institute, said: "We're delighted to be working with Eagle Genomics on this exciting new strategic partnership.
  • Eagle Genomics continues to be engaged in discussions with a range of other organizations to ensure that its platform continues to become the burgeoning global life sciences knowledge discovery hub.
  • Eagle Genomics is forging strategic relationships with leading scientific establishments focused on the microbiome and in the UK has helped shape the Microbiome Strategic Roadmap.

Eagle Genomics and Quadram Institute's New Strategic Partnership to Accelerate Microbiome Analysis Through AI-Augmented Knowledge Discovery Platform

Retrieved on: 
Thursday, January 13, 2022
Knowledge, Population health, Business development, Biotechnology and Biological Sciences Research Council, Nature, Research, Plant, Human, East Anglia, List of genetics research organizations, Food chain, Norwich Research Park, Carbon, Data science, Biology, Earlham Institute, Genomics, BBSRC, Genome, Severe acute respiratory syndrome coronavirus 2, Population, Gene, Soil, Beauty, Deep tech, CEO, Disease, Biotechnology, Microbiology, Health, Bacteria, Tissue, Animal, Reading, Agreement, Food, Environment, Agriculture, Norfolk and Norwich University Hospitals NHS Foundation Trust, Laboratory, Workflow, Organization, Partnership, University of East Anglia, Dietary supplement, Pharmaceutical industry, Antibiotics, Industrial design, Health care, NORWICH, Quadram Institute

CAMBRIDGE and NORWICH, England, Jan. 13, 2022 /PRNewswire/ -- Today, Eagle Genomics, the Deep Tech software business pioneering the application of network science to biology, and the Quadram Institute, a world-leading institute creating new interfaces between food science, gut biology, and human health, are pleased to announce a new partnership committed to promoting the understanding of microbiome science. Building on the agreement announced in September 2021 with the Earlham Institute, a Norwich-based leader in data-intensive bioscience research, the partnership with the Quadram Institute will involve the sharing of datasets, innovation pipelines and tools to facilitate the understanding of complex microbiome data through Eagle Genomics' e[datascientist]™ platform.

Key Points: 
  • "At Eagle Genomics,we firmly believe that the microbiome has a critical role to play across numerous industries, both now and inthe future.
  • Dr. Roberto Zanchi, Head of Business Development, Quadram Institute, said: "We're delighted to be working with Eagle Genomics on this exciting new strategic partnership.
  • Eagle Genomics continues to be engaged in discussions with a range of other organizations to ensure that its platform continues to become the burgeoning global life sciences knowledge discovery hub.
  • Eagle Genomics is forging strategic relationships with leading scientific establishments focused on the microbiome and in the UK has helped shape the Microbiome Strategic Roadmap.

Azzur Group Announces Executive Leadership Changes

Retrieved on: 
Wednesday, January 12, 2022
GDI Integrated Facility Services, Financial services, SR, Biotechnology, COO, Adoption, Growth, Ilya, Solution, Microbiology, Industry, Marketing, Multimedia, GxP, CIO, Professional services, Management, Azur

HATBORO, Pa., Jan. 12, 2022 /PRNewswire/ --To support rapid company growth and best meet the demands of the business, Azzur Group today announces new executive leadership appointments.

Key Points: 
  • HATBORO, Pa., Jan. 12, 2022 /PRNewswire/ --To support rapid company growth and best meet the demands of the business, Azzur Group today announces new executive leadership appointments.
  • Ryan Ott has been promoted to Chief Operating Officer (COO) of Azzur Group.
  • Ilya most recently served as Senior Director of Financial Services and has been a member of Azzur Group since 2016.
  • "I'm incredibly thrilled to announce the changes to the Azzur Group executive leadership team," said Michael Khavinson , Azzur's Chief Executive Officer.

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

Retrieved on: 
Wednesday, January 12, 2022
Biomarker, Doctor of Philosophy, Research, Patient, NBE, Cyber Security Collaborative Research Alliance, Lists of diseases, Government, Vaccine, Cleland, NCE, Dementia, Safety, Central nervous system disease, Health Canada, Food and Drugs Act, Disease, UBC, Neuro, Institute, Standard of care, Alzheimer's disease, Monash University, TRD, OTC, Industry, Good, Medical genetics, Company, Quality of life, University, Central nervous system, Depression, CSE, Food, Patent, Brain, Weather Modification Operations and Research Board, Lancet, Pharmaceutical industry, Management, Microbiology, BC, Psilocybin

VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF)a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced that it has entered into Collaborative Research Agreement (the "Agreement") with the University of British Columbia ("UBC") focussing on Novel Therapies for Neurological Diseases.

Key Points: 
  • VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF)a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced that it has entered into Collaborative Research Agreement (the "Agreement") with the University of British Columbia ("UBC") focussing on Novel Therapies for Neurological Diseases.
  • "We are very excited to announce our second Collaborative Research Agreement focussing on diseases of the brain," stated Dr. Lyle Oberg, MYND's Chief Executive Officer.
  • Cleland's duties will be assumed by Dr. Chahaat Singh who will assume the role of Operations and Research Manager with MYND.
  • ABOUT MYND LIFE SCIENCES INC.
    MYNDLife Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines.

Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants

Retrieved on: 
Tuesday, January 11, 2022
Lung, Patient, Pneumonia, Mount Sinai, Life Science Alliance, MSE, European Molecular Biology Organization, Clinical trial, COVID-19, Icahn School of Medicine at Mount Sinai, Severe acute respiratory syndrome coronavirus 2, Safety, Therapeutic index, PHM, National university, Disease, Department, EMBO, Animal, Rockefeller University, Cold, Viral load, Company, Internal medicine, G.H. Raisoni Department of Microbiology and Biotechnology, European, Hospital, Phase, Hospital das Clínicas, Cold Spring Harbor Laboratory, PharmaMar, Delta, Pulse oximetry, Coronavirus, Omicron, Pharmaceutical industry, Microbiology

MADRID, Jan. 11, 2022 /PRNewswire/ -- PharmaMar (MSE:PHM) has announced today the publication of an article in the Life Science Alliance journal, entitled "Pre-clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19"[1] which includes a study on the in vitro activity of plitidepsin against the main SARS-CoV-2 variants, including the current Omicron variant.

Key Points: 
  • - PharmaMar confirms in vitroactivity of plitidepsin against several variants, including Delta and Omicron.
  • - The Life Science Alliance journal is co-founded by the Rockefeller University, the European Molecular Biology Organization (EMBO) and Cold Spring Harbor Laboratory.
  • The article also reviews data from the APLICOV-PC clinical trial, which demonstrated the safety of plitidepsin in patients with COVID-19 requiring hospital admission.
  • Jos Mara Fernndez Sousa-Faro, Ph.D., PharmaMar's Chairman stated "all the data we have seen so far with plitidepsin corroborate our initial hypothesis about its antiviral activity.

Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants

Retrieved on: 
Tuesday, January 11, 2022
Lung, Patient, Pneumonia, Mount Sinai, Life Science Alliance, MSE, Clinical trial, COVID-19, Icahn School of Medicine at Mount Sinai, Severe acute respiratory syndrome coronavirus 2, Therapeutic index, Safety, PHM, Disease, Department, Animal, Viral load, Internal medicine, G.H. Raisoni Department of Microbiology and Biotechnology, Phase, Hospital, Hospital das Clínicas, PharmaMar, Delta, Pulse oximetry, Coronavirus, Omicron, Pharmaceutical industry, Microbiology

According to the final data published in this article, plitidepsin has been shown to have a potent antiviral activity in all variants at very low (nanomolar) concentrations, with a positive in vitro therapeutic index.

Key Points: 
  • According to the final data published in this article, plitidepsin has been shown to have a potent antiviral activity in all variants at very low (nanomolar) concentrations, with a positive in vitro therapeutic index.
  • Laboratory in vivo studies have also demonstrated a preferential distribution of plitidepsin to lung tissue, which is the organ primarily affected in patients with COVID-19.
  • The article also reviews data from the APLICOV-PC clinical trial, which demonstrated the safety of plitidepsin in patients with COVID-19 requiring hospital admission.
  • Jos Mara Fernndez Sousa-Faro, Ph.D., PharmaMar's Chairman stated "all the data we have seen so far with plitidepsin corroborate our initial hypothesis about its antiviral activity.

PacBio Announces Collaboration with Genomics England to Sequence Biobanked Rare Disease Samples Using HiFi Sequencing Technology

Retrieved on: 
Tuesday, January 11, 2022
Molecule, Securities Exchange Act of 1934, Research, Patient, Abraxis BioScience, Technology, Clinical trial, Genomics England, Genomics, National Health Service, Radboud University Medical Center, Degenerative disease, Genome, NASDAQ, UCLA Health, Pacific Biosciences, Disease, GLOBE, Critical Ecosystem Partnership Fund, NHS, Microbiology, Partnership, U.S. Securities and Exchange Commission, Single-molecule real-time sequencing, Private Securities Litigation Reform Act, Company, Genetic variation, Laboratory, Cancer, Biomedical Research, National Health Service (England), 100,000 Genomes Project, ARUP Laboratories, Security (finance), High fidelity, Genetic distance, Pharmaceutical industry, Antibiotics

Genomics England was initially created to deliver the 100,000 Genomes Project the largest whole genome sequencing disease cohort of cancer and rare disease participants in the National Health Service (NHS).

Key Points: 
  • Genomics England was initially created to deliver the 100,000 Genomes Project the largest whole genome sequencing disease cohort of cancer and rare disease participants in the National Health Service (NHS).
  • The study will re-sequence a selection of samples collected during Genomics Englands 100,000 Genomes Project, which were previously analyzed with short read sequencing technology.
  • The study is intended to reveal potential operational and clinical benefits of long-read sequencing in identifying genetic mutations associated with rare diseases.
  • The 100,000 Genomes Project was able to find actionable mutations in around 25 percent of patients with rare disease, said Parker Moss, Chief Ecosystem & Partnership Officer at Genomics England.

PacBio and Berry Genomics Announce Collaboration to Bring Long Read Desktop Sequencing Instrument to the Clinical Market in China

Retrieved on: 
Tuesday, January 11, 2022
Molecule, Securities Exchange Act of 1934, Research, Technology, Abraxis BioScience, Genomics, NGS, NASDAQ, Pacific Biosciences, GLOBE, Microbiology, Health, U.S. Securities and Exchange Commission, Single-molecule real-time sequencing, Private Securities Litigation Reform Act, Company, Sequel, Genetic variation, Diagnosis, Sale, Biomedical Research, Cancer, NIPT, Laboratory, Security (finance), High fidelity, Hospital, Organization, Lists of diseases, University, Antibiotics, Medical imaging, Pharmaceutical industry

MENLO PARK, Calif. and BEIJING, Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, and Berry Genomics, a leading company in clinical genomics and life science in China, today announced a collaboration to provide PacBio long read sequencing technology to the Chinese clinical market. Under the new agreement, PacBio will develop its first long read desktop sequencing platform with funding and guidance provided by Berry Genomics. When the agreed product requirements are met, Berry Genomics will purchase at least 50 systems for use and sale throughout China.

Key Points: 
  • Under the new agreement, PacBio will develop its first long read desktop sequencing platform with funding and guidance provided by Berry Genomics.
  • The desktop long read sequencing instrument will help Berry Genomics expand its footprint in the perinatal and carrier testing market.
  • This will enable laboratories across China to access PacBio long read sequencing, in an easy-to-use, small footprint desktop format, at a lower capital investment than prior PacBio systems.
  • PacBio and Berry Genomics have had great success with the Sequel II instrument in China, said Dr. Yang Gao, President of Berry Genomics.

PacBio Announces Record Preliminary Fourth Quarter 2021 Revenue, New Sequencing Kits and Workflows, and Expanded Collaborations

Retrieved on: 
Tuesday, January 11, 2022
Molecule, Securities Exchange Act of 1934, Technology, Abraxis BioScience, MRD, Conference, Growth, NASDAQ, SBB, CEO, Pacific Biosciences, GLOBE, DNA, Automation, Methylation, U.S. Securities and Exchange Commission, Microbiology, Goal, Liquid biopsy, Private Securities Litigation Reform Act, Company, Sequel, Genetic variation, Biomedical Research, Twist Bioscience, Software, Security (finance), Workflow, High fidelity, COVID, Video game

The Companys full financial results for the fourth quarter and the fiscal year ended December 31, 2021, are not yet available.

Key Points: 
  • The Companys full financial results for the fourth quarter and the fiscal year ended December 31, 2021, are not yet available.
  • Expect preliminary fourth quarter revenue of approximately $36.0 million, representing an increase of approximately 33% compared with $27.1 million for the fourth quarter of 2020.
  • Placed a record of 48 Sequel II/IIe systems during the fourth quarter compared to 35 Sequel II/IIe systems placed in the prior year quarter.
  • Preliminary instrument revenue for the fourth quarter of 2021 is expected to be approximately $16.2 million, compared with $15.9 million for the third quarter of 2021, and compared with $13.6 million for the fourth quarter of 2020.